The CCG is mandated with providing sustainable and scalable clinical diagnostic genomic testing for the BC population.
The CCG aims to implement emerging technologies to provide the most cost-effective clinical testing for genetic disease. The CCG will embrace personalized medicine through a strong integration of technology and informatics.
Myeloid panel updated to include KMT2A(MLL) PTD detection
The CCG is continually improving its panels and adding mutations with clinical significance. We have added Partial Tandem Duplication (PTD) detection for KMT2A which has been requested by the clinicians using our panels.
The Centre for Clinical Genomics awarded $2 million grant for more efficient genomic test delivery
The BC Cancer Agency’s Centre for Clinical Genomics (CCG) at the Genome Sciences Centre was recently awarded a Genome BC Health Exemplar Strategy grant entitled “Automation of the Clinical Bioinformatics Pipeline at the Centre for Clinical Genomics.” Co-funded by the Provincial Health Services Authority (PHSA), the $2 million project over three years will address the need for more automation and analysis software to make genomic testing available to a greater number of people.
More information can be found on Genome BC's website
CCG maintains CAP accreditation for the fourth time
The Centre for Clinical Genomics (CCG) has achieved full accreditation from the College of American Pathologists (CAP) for the fourth time after passing its unannounced biennial on-site inspection. The inspectors visited the laboratory on January 30, 2017 and were very impressed with the lab as a whole, and specifically commented on the dedication of the team to quality assurance. The inspection included examination of the laboratory's records and quality control of procedures for the preceding two years. CAP inspectors also examined laboratory staff qualifications, equipment, facilities, safety program and record, and overall management. CAP accreditation is vital in demonstrating that CCG meets and exceeds clinical quality standards in its next-generation sequencing (NGS) lab and is therefore able to deliver clinical testing with a high impact on patient care.
More information can be found at www.cap.org.
Oncopanel and Myeloid panel available to oncologists and haematologists across British Columbia
The Centre for Clinical Genomics (CCG) is pleased to announce its 26 gene Oncopanel and 42 gene Myeloid Panel is now available to patients.
More information can be found on BC Cancer Agency website
CCG successfully maintains CAP accreditation
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to CCG based on results of a recent on-site inspection as part of the CAP's Accreditation Programs. The inspection included examination of the laboratory's records and quality control of procedures for the preceding two years. CAP inspectors also examined laboratory staff qualifications, equipment, facilities, safety program and record, and overall management. CCG was first accredited in 2011 and is one of more than 7,600 CAP-accredited facilities worldwide. More information can be found at www.cap.org.
We have received funding from Genome BC to carry out a project entitled Application of DNA microarray technologies to clinical testing in hereditary cancer syndromes. This will enable the improvement of our 14 gene panel to detect copy number alterations (CNA) using a platform which is scalable and sustainable.
More information can be found on Genome BC's website
The Centre for Clinical Genomics (CCG) is pleased to announce its 14 gene Hereditary Cancer Panel is now available to patients. This panel replaced BRCA1/2 testing in British Columbia in October 2014.
The Excellence in BC Health Care Awards honoured CCG with a 2014 Golden Apple Award for Top Innovation - Health Authority. Presented by the Health Employers Association of British Columbia (HEABC), the Awards reward innovation and best practices within BC's publicly funded health care providers.